CCM

Concord Medical Services Holdings Ltd. - 20-F Filing Summary

Business Context and Reporting Period

Company: Concord Medical Services Holdings Ltd. (NYSE: CCM)
Reporting Period: Fiscal year ended December 31, 2010
Jurisdiction: Cayman Islands (Operations primarily in the People's Republic of China)
Business Model: The company operates the largest network of radiotherapy and diagnostic imaging centers in China. It primarily enters into long-term lease and management services arrangements with hospitals, purchasing medical equipment and leasing it to hospital partners while managing the centers. In exchange, Concord receives a contracted percentage of the center's revenue net of specified operating expenses. The company is also expanding into majority-owned specialty cancer hospitals.

Key Financial Metrics (Year Ended Dec 31, 2010)

Note: US Dollar amounts are translated at the rate of RMB 6.6000 to US$1.00, the noon buying rate as of December 30, 2010.

Material Changes vs. Prior Period

• Revenue Growth: Total net revenues increased 33.2% to RMB 389.5 million, driven by a 10% increase in patient cases at existing centers and the opening of 33 new centers in 2010.
• Margin Compression: Gross margin decreased from 70.1% to 68.5%, and operating margin decreased from 57.2% to 46.1%. This was primarily due to higher costs associated with new centers in their ramp-up period and a shift toward diagnostic imaging services, which have lower margins than radiotherapy.
• Expense Surge: Operating expenses increased 132.4% to RMB 87.2 million. This significant rise was attributed to increased headcount, professional fees associated with being a public company, and a RMB 8.6 million increase in share-based compensation expenses.
• Cash Position: Cash balances decreased significantly from RMB 1.04 billion in 2009 to RMB 535.8 million in 2010. The decline was primarily due to heavy capital expenditures (RMB 405.0 million) for purchasing medical equipment and acquiring new centers, as well as share repurchases.
• Foreign Exchange: The company recorded a foreign exchange loss of RMB 5.4 million in 2010, compared to RMB 0.2 million in 2009, due to the depreciation of U.S. dollar-denominated cash balances against the Renminbi.

Guidance, Outlook, and Risks

Outlook and Strategy: The company plans to continue expanding its network of centers and establishing specialty cancer hospitals. It estimates aggregate capital expenditures for 2011 to be between RMB 500 million and RMB 600 million. The company intends to fund these activities through cash flows from operations and existing cash balances, though it may seek additional financing if necessary.

Material Risks and Contingencies:

• Internal Control Weaknesses: Management identified a material weakness in internal control over financial reporting. The independent auditor issued an adverse opinion on the effectiveness of internal controls as of December 31, 2010. This poses a risk of material misstatements in future financial statements.
• Regulatory Compliance: The company faces risks regarding the conversion of "cooperation agreements" with non-profit hospitals into "lease and management agreements" to comply with PRC regulations. Failure to convert these agreements could result in penalties or suspension of operations. Additionally, the company relies on government quotas for the procurement of large medical equipment (e.g., Gamma Knife, PET-CT), which limits expansion.
• Intellectual Property Litigation: A legal proceeding alleges that a head gamma knife system in one center infringes on a third-party patent. While the manufacturer has agreed to indemnify Concord and the patent was recently nullified by the Patent Reexamination Board (currently under appeal), the outcome remains uncertain.
• Revenue Concentration: The top five hospital partners accounted for 31.8% of total net revenues in 2010, with the largest partner contributing 12.3%. Loss of these partners would materially impact the business.
• Healthcare Reform: PRC government policies aiming to reduce examination and treatment fees for large medical equipment could adversely affect revenue.

Key Facts for Investor Verification

• Internal Control Status: Verify the progress of remediation efforts regarding the material weakness in internal controls that led to an adverse audit opinion.
• Regulatory Quotas: Monitor the availability of procurement licenses for Class A and Class B medical equipment, as these quotas directly constrain the company's ability to open new centers.
• Agreement Conversions: Track the status of converting remaining cooperation agreements with non-profit hospitals to lease and management agreements to ensure regulatory compliance.
• Capital Expenditure Execution: Assess whether the planned RMB 500-600 million capital expenditure for 2011 is being executed as anticipated and if it yields expected returns.
• Share Repurchase Program: Note that the company completed a share repurchase program in Q4 2010, buying back 1.7 million ADSs for US$11.4 million.